LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | A443654 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 728 | 3769 | 0.1933 | -0.1379 |
BT-20 | OSI-027 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 2380 | 3769 | 0.6314 | 0.4800 |
BT-20 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1097 | 2986 | 3769 | 0.7922 | 0.7069 |
BT-20 | HG-6-64-01 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 2594 | 3769 | 0.6882 | 0.5602 |
BT-20 | WH-4-025 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 2814 | 3769 | 0.7467 | 0.6427 |
BT-20 | WZ-4-145 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 2672 | 3769 | 0.7089 | 0.5894 |
BT-20 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 1323 | 3769 | 0.3512 | 0.0847 |
BT-20 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3699 | 3769 | 0.9813 | 0.9736 |
BT-20 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 1950 | 3769 | 0.5175 | 0.3194 |
BT-20 | BX-912 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3616 | 3769 | 0.9594 | 0.9427 |
BT-20 | Canertinib | 0.37 | uM | LJP6 | 72 | hr | 1097 | 3100 | 3769 | 0.8224 | 0.7495 |
BT-20 | Celastrol | 0.37 | uM | LJP6 | 72 | hr | 1097 | 3235 | 3769 | 0.8584 | 0.8002 |
BT-20 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 716 | 3769 | 0.1900 | -0.1426 |
BT-20 | CGP60474 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 643 | 3769 | 0.1707 | -0.1699 |
BT-20 | CHIR-99021 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 3245 | 3769 | 0.8609 | 0.8037 |
BT-20 | CP724714 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3643 | 3769 | 0.9665 | 0.9528 |
BT-20 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3786 | 3769 | 1.0044 | 1.0062 |
BT-20 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3267 | 3769 | 0.8668 | 0.8121 |
BT-20 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3474 | 3769 | 0.9216 | 0.8894 |
BT-20 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 1463 | 3769 | 0.3881 | 0.1369 |
BT-20 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1097 | 1109 | 3769 | 0.2943 | 0.0045 |
BT-20 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 1624 | 3769 | 0.4310 | 0.1974 |
BT-20 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1097 | 4103 | 3769 | 1.0886 | 1.1249 |
BT-20 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3329 | 3769 | 0.8832 | 0.8353 |
BT-20 | Foretinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 1634 | 3769 | 0.4335 | 0.2009 |